332 related articles for article (PubMed ID: 29769386)
21. The Global Landscape of Manufacturers of Follow-on Biologics: An Overview of Five Major Biosimilar Markets and 15 Countries.
Klein K; Gencoglu M; Heisterberg J; Acha V; Stolk P
BioDrugs; 2023 Mar; 37(2):235-245. PubMed ID: 36472773
[TBL] [Abstract][Full Text] [Related]
22. The rise of biosimilars: potential benefits and drawbacks in rheumatoid arthritis.
Yoo DH
Expert Rev Clin Immunol; 2014 Aug; 10(8):981-3. PubMed ID: 24961712
[TBL] [Abstract][Full Text] [Related]
23. Biosimilars: what the oncologist should know.
Thill M; Thatcher N; Hanes V; Lyman GH
Future Oncol; 2019 Apr; 15(10):1147-1165. PubMed ID: 30793950
[TBL] [Abstract][Full Text] [Related]
24. Rituximab biosimilars.
Vital EM; Kay J; Emery P
Expert Opin Biol Ther; 2013 Jul; 13(7):1049-62. PubMed ID: 23600760
[TBL] [Abstract][Full Text] [Related]
25. Pharmacist perspectives and considerations for implementation of therapeutic oncology biosimilars in practice.
Cuellar S; McBride A; Medina P
Am J Health Syst Pharm; 2019 Oct; 76(21):1725-1738. PubMed ID: 31612935
[TBL] [Abstract][Full Text] [Related]
26. Biosimilars: Practical Considerations for Pharmacists.
Stevenson JG; Popovian R; Jacobs I; Hurst S; Shane LG
Ann Pharmacother; 2017 Jul; 51(7):590-602. PubMed ID: 28176529
[TBL] [Abstract][Full Text] [Related]
27. Use of Biologics and Biosimilars in Rheumatology.
Sharma SK
J Assoc Physicians India; 2017 May; 65(5 Suppl):9-14. PubMed ID: 28836745
[TBL] [Abstract][Full Text] [Related]
28. Opportunities and challenges in biosimilar uptake in oncology.
Dolan C
Am J Manag Care; 2018 Jun; 24(11 Suppl):S237-S243. PubMed ID: 29957909
[TBL] [Abstract][Full Text] [Related]
29. Safety of Biologics, Including Biosimilars: Perspectives on Current Status and Future Direction.
Ingrasciotta Y; Cutroneo PM; Marcianò I; Giezen T; Atzeni F; Trifirò G
Drug Saf; 2018 Nov; 41(11):1013-1022. PubMed ID: 29796832
[TBL] [Abstract][Full Text] [Related]
30. Biosimilar insulins: a European perspective.
DeVries JH; Gough SC; Kiljanski J; Heinemann L
Diabetes Obes Metab; 2015 May; 17(5):445-51. PubMed ID: 25376600
[TBL] [Abstract][Full Text] [Related]
31. Regulatory and clinical considerations for biosimilar oncology drugs.
Bennett CL; Chen B; Hermanson T; Wyatt MD; Schulz RM; Georgantopoulos P; Kessler S; Raisch DW; Qureshi ZP; Lu ZK; Love BL; Noxon V; Bobolts L; Armitage M; Bian J; Ray P; Ablin RJ; Hrushesky WJ; Macdougall IC; Sartor O; Armitage JO
Lancet Oncol; 2014 Dec; 15(13):e594-e605. PubMed ID: 25456378
[TBL] [Abstract][Full Text] [Related]
32. Biosimilars for inflammatory bowel disease: how can healthcare professionals help address patients' concerns?
Gecse KB; Cumming F; D'Haens G
Expert Rev Gastroenterol Hepatol; 2019 Feb; 13(2):143-155. PubMed ID: 30791783
[TBL] [Abstract][Full Text] [Related]
33. The complexities of biosimilars and the regulatory approval process.
Lucio S
Am J Manag Care; 2018 Jun; 24(11 Suppl):S231-S236. PubMed ID: 29957908
[TBL] [Abstract][Full Text] [Related]
34. Demystifying biosimilars: development, regulation and clinical use.
Rugo HS; Rifkin RM; Declerck P; Bair AH; Morgan G
Future Oncol; 2019 Mar; 15(7):777-790. PubMed ID: 30500264
[TBL] [Abstract][Full Text] [Related]
35. Biosimilars: Opportunities to Promote Optimization Through Payer and Provider Collaboration.
Manolis CH; Rajasenan K; Harwin W; McClelland S; Lopes M; Farnum C
J Manag Care Spec Pharm; 2016 Sep; 22(9 Suppl):S3-9. PubMed ID: 27579939
[TBL] [Abstract][Full Text] [Related]
36. Clinical and Regulatory Considerations for the Use of Bevacizumab Biosimilars in Metastatic Colorectal Cancer.
Taïeb J; Aranda E; Raouf S; Dunn H; Arnold D
Clin Colorectal Cancer; 2021 Mar; 20(1):42-51.e3. PubMed ID: 33243618
[TBL] [Abstract][Full Text] [Related]
37. A Clinical Review of Biosimilars Approved in Oncology.
Ngo D; Chen J
Ann Pharmacother; 2021 Mar; 55(3):362-377. PubMed ID: 32715722
[TBL] [Abstract][Full Text] [Related]
38. Current state and comparison of the clinical development of bevacizumab, rituximab and trastuzumab biosimilars.
Díaz LP; Millán S; Chaban N; Campo AD; Spitzer E
Future Oncol; 2021 Jul; 17(19):2529-2544. PubMed ID: 33904318
[TBL] [Abstract][Full Text] [Related]
39. Biosimilars: From Production to Patient.
Sheridan M; Massich M; Ashourian N
J Infus Nurs; 2024 Jan-Feb 01; 47(1):19-29. PubMed ID: 38211611
[TBL] [Abstract][Full Text] [Related]
40. Biosimilars-Emerging Role in Nephrology.
Wish JB
Clin J Am Soc Nephrol; 2019 Sep; 14(9):1391-1398. PubMed ID: 30082337
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
